December 3, 2018

On December 1, Precision BioLogic unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the 60th ASH Annual Meeting in San Diego, CA.

Recognizing the need to standardize and improve Factor VIII (FVIII) inhibitor testing for people with hemophilia A, the company developed the new MNBA kit in collaboration with Roche and Genentech, a member of the Roche Group. Precision BioLogic plans to commercialize the kit as the CRYOcheck™ FVIII Inhibitor Kit and will soon seek clearance from regulatory authorities around the globe.

A poster of the latest study, A Standardized Kit for a Chromogenic Modified Nijmegen-Bethesda Assay: Repeatability, Reproducibility, and Analytical Sensitivity, as well as previous studies, can be downloaded from the publications page of the Precision BioLogic website.